Jennison Associates
AVDL

Jennison Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Jennison Associates’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-726,586
Closed -$11.9M – 660
2015
Q3 		$11.9M Buy
726,586
+5,626
+0.8% +$124K 0.01% 492
2015
Q2 		$15.3M Buy
720,960
+7,190
+1% +$129K 0.01% 486
2015
Q1 		$12.8M Buy
713,770
+2,263
+0.3% +$35.4K 0.01% 485
2014
Q4 		$12.2M Sell
711,507
-776
-0.1% -$11.1K 0.01% 476
2014
Q3 		$10.2M Sell
712,283
-107,504
-13% -$1.55M 0.01% 483
2014
Q2 		$12.3M Sell
819,787
-680,213
-45% -$8.2M 0.01% 468
2014
Q1 		$20.1M Buy
+1,500,000
New +$16.1M 0.02% 442

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

Jennison Associates's AVDL Position: Q4 2015 in Review

Jennison Associates sold out of Avadel Pharmaceuticals (AVDL) in Q4 2015, closing a stake of 726,586 shares — an estimated $11.9M sold.

Jennison Associates first reported a position in AVDL in Q1 2014 and held it in 7 quarters. The position peaked at $20.1M in Q1 2014. 89 funds tracked by Wall St. Rank hold AVDL as of Q4 2015.

  • Jennison Associates reported no remaining Avadel Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Jennison Associates sold 726,586 Avadel Pharmaceuticals shares in Q4 2015, an estimated $11.9M.
  • Jennison Associates first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 7 quarters.
  • Jennison Associates's Avadel Pharmaceuticals position peaked at $20.1M in Q1 2014.
  • 89 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2015.

Based on Jennison Associates's 13F filing for Q4 2015, filed 10 Feb 2016.